NASDAQ:BMRA - Biomerica Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.33
  • Forecasted Upside: 106.06 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.50
▼ -0.34 (-5.82%)
1 month | 3 months | 12 months
Get New Biomerica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.33
▲ +106.06% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Biomerica in the last 3 months. The average price target is $11.33, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 106.06% upside from the last price of $5.50.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Biomerica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2021B. RileyLower Price TargetBuy$11.00 ➝ $10.00High
i
11/10/2020Colliers SecuritiesInitiated CoverageBuy$13.00High
i
Rating by K. Bauser at Colliers Securities
10/19/2020AegisLower Price TargetBuy$13.00 ➝ $11.00Low
i
9/4/2020AegisBoost Price TargetBuy$10.00 ➝ $13.00High
i
8/21/2020AegisInitiated CoverageBuy$10.00Low
i
6/5/2020B. RileyBoost Price Target$6.25 ➝ $11.00High
i
10/21/2019B. RileySet Price TargetBuy$6.30Low
i
Rating by Andrew D'silva at B. Riley
9/10/2019B. RileySet Price TargetBuy$6.00High
i
Rating by Andrew D'silva at B. Riley
7/19/2019B. RileySet Price TargetBuy$6.00N/A
i
Rating by Andrew D'silva at B. Riley
12/17/2018B. RileyLower Price TargetBuy ➝ Buy$7.50 ➝ $6.25Medium
i
1/4/2018B. RileyInitiated CoverageBuy ➝ Buy$7.50High
i
Rating by A. D'silva at B. Riley
(Data available from 3/5/2016 forward)
Biomerica logo
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $5.50
$5.18
$5.79

50 Day Range

MA: $6.87
$5.70
$8.00

52 Week Range

Now: $5.50
$2.05
$23.39

Volume

143,908 shs

Average Volume

530,789 shs

Market Capitalization

$64.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biomerica?

The following Wall Street sell-side analysts have issued research reports on Biomerica in the last year: Aegis, B. Riley, and Colliers Securities.
View the latest analyst ratings for BMRA.

What is the current price target for Biomerica?

3 Wall Street analysts have set twelve-month price targets for Biomerica in the last year. Their average twelve-month price target is $11.33, suggesting a possible upside of 106.1%. Colliers Securities has the highest price target set, predicting BMRA will reach $13.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $10.00 for Biomerica in the next year.
View the latest price targets for BMRA.

What is the current consensus analyst rating for Biomerica?

Biomerica currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMRA will outperform the market and that investors should add to their positions of Biomerica.
View the latest ratings for BMRA.

What other companies compete with Biomerica?

How do I contact Biomerica's investor relations team?

Biomerica's physical mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company's listed phone number is (949) 645-2111. The official website for Biomerica is www.biomerica.com.